Rhythm Pharmaceuticals Inc RYTM:NASDAQ

Last Price$3.27NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22

Today's Change+0.15(4.81%)
Bid (Size)$3.15 (2)
Ask (Size)$3.28 (71)
Day Low / High$3.04 - 3.28
Volume483.5 K

View Biotechnology IndustryPeer Comparison as of 05/20/2022


Rhythm Pharmaceuticals Inc ( NASDAQ )

Price: $3.27
Change: +0.15 (4.81%)
Volume: 483.5 K
4:00PM ET 5/20/2022

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $2.85
Change: +0.23 (8.78%)
Volume: 835.2 K
4:00PM ET 5/20/2022

Co-Diagnostics Inc ( NASDAQ )

Price: $4.99
Change: +0.02 (0.40%)
Volume: 211.0 K
4:00PM ET 5/20/2022

XBiotech Inc ( NASDAQ )

Price: $5.61
Change: -0.11 (1.92%)
Volume: 94.3 K
4:00PM ET 5/20/2022

Armata Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $4.25
Change: -0.10 (2.30%)
Volume: 1.3 K
8:00PM ET 5/20/2022

Read more news Recent News

--Goldman Sachs Adjusts Price Target for Rhythm Pharmaceuticals to $9 From $10, Maintains Neutral Rating
1:25PM ET 4/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Finish Higher on Wednesday
4:10PM ET 4/06/2022 MT Newswires

Health care stocks continued to add their Wednesday advance, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) rising 1.9%...

Update: Rhythm Pharma Modifies Trials of Genetic Obesity Medicine; Shares Drop
3:01PM ET 4/06/2022 MT Newswires

(Updates with share price in the headline and last paragraph) Rhythm Pharmaceuticals (RYTM) said Wednesday it has modified phase 2 and 3 trials evaluating...

Sector Update: Health Care Stocks Climbing Wednesday Afternoon
2:07PM ET 4/06/2022 MT Newswires

Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 1.0%. ...

Company Profile

Business DescriptionRhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The firm focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA. View company web site for more details
Address222 Berkeley Street
Boston, Massachusetts 02116-3748
Number of Employees54
Recent SEC Filing05/03/202210-Q
Chairman, President & Chief Executive OfficerDavid P. Meeker
Chief Financial Officer & TreasurerHunter C. Smith
Vice President-Medical AffairsBrieana Buckley
Chief Technical OfficerJoseph Shulman

Company Highlights

Price Open$3.18
Previous Close$3.12
52 Week Range$3.04 - 22.48
Market Capitalization$164.8 M
Shares Outstanding50.4 M
SectorHealth Technology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.30
Beta vs. S&P 500N/A
Net Profit Margin-3,598.16%
Return on Equity-55.66%

Analyst Ratings as of 03/04/2022

Consensus RecommendationConsensus Icon
Powered by Factset